Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

NCT02957396 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics

Interventions

DRUG: Finerenone (BAY94-8862): 20 mg intact tablet
DRUG: Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet
DRUG: Finerenone (BAY94-8862): 20 mg suspension

Sponsor

Bayer